As director of clinical trials, Sheth has served as principal investigator on more than 100 clinical trials, advancing ...
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
ARCHER data reveal which GA eyes risk major vision loss: midrange baseline acuity and subfoveal lesions, shaping counseling ...
How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
Introducing Nicholas Riina, MS. Nicholas Riina, MS, had his eye on the prize early on, growing up in a family in which he was ...
Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...
OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular ...
In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about ...
Esen Akpek, MD, on dry eye's emotional and vision-related toll, its hidden autoimmune links, and when to move patients beyond ...
Published online in April in JAMA Ophthalmology, the phase 3 CONDOR trial (NCT04278417) found that brolucizumab (Beovu; ...
Bausch + Lomb announced topline results from its phase 2 study of BL1107 in patients with glaucoma. According to the company, the trial did not achieve its primary endpoint of rep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results